Clinical Trial

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Study acronym: ZEBRA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-11-22; most recent amendment 2025-04-15.
Status change: Not Yet Recruiting → Recruiting 2024-06-07
Trial Details
NCT Number NCT05635162
Lead Sponsor University College, London
Collaborators: BeiGene
Conditions Mantle Cell Lymphoma
Enrollment 50 participants
Start Date 2024-05-17
Primary Completion 2028-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-16